Healthcare / Medical Instruments & SuppliesKuala Lumpur
$0.54
-0.00 (-0.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $58.7M · quality 75.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$332M
P/E
9.0x
↓EV/EBITDA
4.1x
↓ROE
23.0%
↑Gross Margin
65.5%
↑Debt/Equity
0.93
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.8%
FCF CAGR
+7.4%
FCF margin
23.9%
FCF / Net income
2.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $311.4M · net income $35.0M · FCF $74.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $311.4M | $311.4M | $292.5M | $260.9M | $248.8M |
| Net Income | $35.0M | $35.0M | $33.2M | $30.1M | $35.9M |
| EBITDA | $103.6M | $103.6M | $95.4M | $89.9M | $90.5M |
| EPS | 0.06 | 0.06 | 0.05 | 0.05 | 0.06 |
| Gross Margin | 65.5% | 65.5% | 63.8% | 64.9% | 65.3% |
| Operating Margin | 17.9% | 17.9% | 17.2% | 17.9% | 21.3% |
| Net Margin | 11.2% | 11.2% | 11.3% | 11.6% | 14.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.93 | 0.93 | 0.93 | 1.03 | 1.20 |
| Current Ratio | 1.87 | 1.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $74.4M | $74.4M | $58.7M | $48.4M | $60.1M |
| Returns | |||||
| ROE | 23.0% | 23.0% | 24.6% | 25.6% | 35.3% |
| Valuation | |||||
| P/E | 9.00 | 9.00 | 11.13 | 11.10 | 9.20 |
| EV/EBITDA | 4.11 | 4.11 | 4.79 | 4.67 | 4.86 |
| P/B | 2.18 | 2.18 | 2.74 | 2.84 | 3.24 |
| Growth & Yield | |||||
| Revenue Growth | 6.4% | 6.4% | 12.1% | 4.9% | — |
| EPS Growth | 5.6% | 5.6% | 10.1% | -15.9% | — |
| Dividend Yield | 5.6% | 5.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-5.6%
EPS terminal req.
$0.05
Spread vs growth
11.1%
5Y implied EPS CAGR
0.4%
EPS terminal req.
$0.06
Spread vs growth
5.2%
10Y implied EPS CAGR
5.1%
EPS terminal req.
$0.09
Spread vs growth
0.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.3%
Start / end P/E
10.6x → 9.5x
EPS bridge
0.05 → 0.06
Residual
-0.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.